Andrographolide, taken intraperitoneally at a dose of 2.0 mg/kg, substantially alleviated pathological and behavioral abnormalities, which implies AD in both APP/PS1 mice and elderly degus (56-month-old) as demonstrated in the in vivo studies (Serrano et al., 2014; Rivera et al., 2016). Here, APP is linked to Alzheimer disease.